The University of Hyderabad (UoH) and Krismo Biosciences Private Limited, a promising biotechnology start-up incubated at ASPIRE-BioNEST, today announced a collaboration aimed at developing next-generation therapies for inflammatory diseases and serious infectious conditions.

The partnership will see the two institutions leverage their respective expertise to research and develop innovative therapeutic products targeting a range of inflammatory disorders. A key focus will also be on the design of antibody-based therapies to effectively combat viral infections, including Dengue, COVID-19, and Influenza, as well as potent toxins produced by harmful bacteria responsible for debilitating conditions like gas gangrene. The agreement outlines a collaborative approach to develop novel therapeutics, encompassing preclinical toxicology and non-GLP studies, with the shared goal of applying for relevant research grants.

Speaking at the signing ceremony, Prof. Nooruddin Khan, faculty, Department of Animal Biology, School of Life Sciences, University of Hyderabad, emphasized the synergy of the collaboration, stating, "This partnership represents the best of both worlds — academic excellence and industry innovation — coming together to address urgent healthcare challenges." Dr Krishna Mohan, CEO of Krismo Biosciences, echoed this sentiment, expressing his optimism that the collaboration would yield practical, affordable, and impactful solutions for patients.

The initiative was facilitated by the University’s Technology Enabling Centre (UoH-TEC), established with support from the Department of Science and Technology (DST), Government of India. Prof. S. Rajagopal, Project Coordinator of UoH-TEC, highlighted the center's role in fostering such collaborations, stating to the press, "We are actively encouraging our faculty members to translate their valuable knowledge into tangible technologies and products that can critically address pressing societal needs.

" Prof. Rajagopal also expressed his gratitude to the DST for recognizing UoH for this important initiative and affirmed UoH-TEC's commitment to connecting academic innovators with established industry partners to bring their innovations to the forefront. Dr. Sunil, Principal Scientific Officer at UoH-TEC, and Dr. Anil Kondreddy, CEO of ASPIRE-BioNEST, attended the agreement ceremony.

The agreement underscores the increasing momentum of translational academic research in India and highlights the crucial role of public-private partnerships in driving forward medical innovations for the benefit of society.